An Anti-Psychotic Drug With its Own Issues: AstraZeneca’s Seroquel – German Patent Tossed

by YCharts Staff November 14, 2012

AstraZeneca’s (AZN) big selling Seroquel, an anti-psychotic drug with annual sales well over $1 billion, suffered the loss of its German patent, according to an AP news dispatch.

The setback comes in the wake of questions about Seroquel’s heavy prescribing by the U.S. military for off-label uses, as YCharts has reported.

AZN data by YCharts

AstraZeneca has struggled more than most drug makers – more, according to this brilliant Forbes analysis, than Pfizer (PFE), GlaxoSmithKline (GSK), Sanofi (SNY) or Johnson & Johnson (JNJ) -- to develop new drugs and replace those with expiring patents.

From the editors of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.

Filed under: Company Analysis